No evidence for genetic role of the tumor necrosis factor pathway in Parkinson’s disease
Tumor necrosis factor (TNF) inhibition is under investigation as a therapeutic strategy for Parkinson's disease (PD) and REM sleep behavior disorder (RBD), yet supporting genetic evidence is limited. We used Summary-data-based Mendelian Randomization (SMR) to test whether expression level of ten TNF-related genes were causally linked to PD risk, PD progression, or RBD risk. We also analyzed associations between common and rare variants in these genes, and performed pathway specific polygenic risk score analysis, with PD. Overall, our findings do not support a genetic link between the TNF signaling and PD or RBD, arguing against this pathway as a genetically validated therapeutic target.
Authors
- Konstantin A. Senkevich (ORCID: https://orcid.org/0000-0003-3407-5716)
- Alastair John Noyce (ORCID: https://orcid.org/0000-0003-3027-5497)
- Emma N. Somerville (ORCID: https://orcid.org/0000-0002-5892-8069)
- Ziv Gan‐Or (ORCID: https://orcid.org/0000-0003-0332-234X)
- Lang Liu (ORCID: https://orcid.org/0009-0007-8868-701X)
- Morvarid Ghamgosar Shahkhali
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Queen Mary University of London (GB)
- Barts Health NHS Trust (GB)
- Royal London Hospital (GB)
- McGill University Health Centre (CA)
- McGill University (CA)
Publication Details
- Journal
- npj Parkinson s Disease
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1038/s41531-025-01197-4
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- Michael J. Fox Foundation for Parkinson's Research
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Celgene
- Verily Life Sciences
- National Institutes of Health
- Fonds de Recherche du Québec - Santé
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke